Sagetis Biotech Overview

  • Founded
  • 2010
Founded
  • Status
  • Out of Business
  • Employees
  • 2
Employees
  • Latest Deal Type
  • Out of Business

Sagetis Biotech General Information

Description

Developer of a polymeric technology intended to overcome a fundamental engineering challenge in gene therapy. The company's technology develops polymer-coated adenovirus which is protected against pre-existing neutralizing antibodies, by masking their surface antigenic epitopes, while preserving their transduction capability, for the treatment of pancreatic ductal adenocarcinoma, enabling healthcare professionals to modify the behavior of oncolytic viruses, improving their therapeutic effect by different means.

Contact Information

Website
www.sagetis-biotech.com
Ownership Status
Out of Business
Financing Status
Formerly VC-backed
Primary Industry
Biotechnology
Other Industries
Drug Delivery
Drug Discovery
Primary Office
  • Via Augusta, 394
  • 08017 Barcelona
  • Spain
+34 933 00 00 00
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Sagetis Biotech Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
4. Out of Business 09-Jul-2021 00.000 Completed Out of Business
3. Grant 22-Dec-2017 00.000 Completed Generating Revenue
2. Seed Round 15-Jul-2013 $2.61M $2.61M Completed Generating Revenue
1. Seed Round 15-Dec-2011 Completed Generating Revenue
To view Sagetis Biotech’s complete valuation and funding history, request access »

Sagetis Biotech Patents

  • 17

    Total Documents Applications and Grants

  • 000

    Total Patents Families

  • 1

    Granted

  • 000

    Pending

  • 000

    Expiring in next 12 mo

Sagetis Biotech Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
GB-201708203-D0 Chemical compounds Ceased 22-May-2017 0000000000
AU-2018274622-A1 Complexes of viral-based therapeutic agents and modified poly(beta-amino ester)s Pending 22-May-2017 0000000000
CA-3064482-A1 Complexes of viral-based therapeutic agents and modified poly(beta-amino ester)s Pending 22-May-2017 0000000000
JP-2020520967-A Conjugates of virus-based therapeutics with modified poly(β-aminoesters) Pending 22-May-2017 0000000000
US-20200147237-A1 Complexes of viral-based therapeutic agents and modified poly(beta-amino ester)s Pending 22-May-2017 A61K47/593
To view Sagetis Biotech’s complete patent history, request access »

Sagetis Biotech Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Ready to get started?

Request a free trial